US 9,808,460 B2
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
Jay Lichter, Rancho Santa Fe, CA (US); Andrew M. Trammel, Olathe, KS (US); Fabrice Piu, San Diego, CA (US); Qiang Ye, San Diego, CA (US); Benedikt Vollrath, San Diego, CA (US); Luis A. Dellamary, San Marcos, CA (US); Carl Lebel, Malibu, CA (US); and Jeffrey P. Harris, La Jolla, CA (US)
Assigned to OTONOMY, INC., San Diego, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by Otonomy, Inc., San Diego, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on May 15, 2015, as Appl. No. 14/713,944.
Application 14/713,944 is a continuation of application No. 13/928,157, filed on Jun. 26, 2013, granted, now 9,066,855.
Application 13/928,157 is a continuation of application No. 12/504,553, filed on Jul. 16, 2009, granted, now 8,496,957, issued on Jul. 30, 2013.
Claims priority of provisional application 61/082,450, filed on Jul. 21, 2008.
Claims priority of provisional application 61/083,830, filed on Jul. 25, 2008.
Claims priority of provisional application 61/086,094, filed on Aug. 4, 2008.
Claims priority of provisional application 61/094,384, filed on Sep. 4, 2008.
Claims priority of provisional application 61/101,112, filed on Sep. 29, 2008.
Claims priority of provisional application 61/140,033, filed on Dec. 22, 2008.
Claims priority of provisional application 61/160,233, filed on Mar. 13, 2009.
Claims priority of provisional application 61/164,812, filed on Mar. 30, 2009.
Claims priority of provisional application 61/174,421, filed on Apr. 30, 2009.
Claims priority of application No. 0907070.7 (GB), filed on Apr. 24, 2009.
Prior Publication US 2016/0038491 A1, Feb. 11, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/10 (2006.01); A61K 31/4704 (2006.01); A61K 31/517 (2006.01); A61K 31/47 (2006.01); A61K 47/10 (2017.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 31/137 (2006.01); A61K 31/4535 (2006.01); A61K 47/32 (2006.01); A61K 31/135 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 9/0046 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/4535 (2013.01); A61K 31/47 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An intratympanic composition for use in the treatment of otic disorders by intratympanic administration on or near the round window membrane of the ear, the pharmaceutical composition comprising an auris acceptable gel and a multiparticulate non-microencapsulated glutamate receptor antagonist, wherein sustained release of the glutamate receptor antagonist into the cochlea occurs for a period of at least 3 days.